Skip to main content
Top
Published in: Journal of Neural Transmission 6/2017

01-06-2017 | Neurology and Preclinical Neurological Studies - Original Article

Benefit on motor and non-motor behavior in a specialized unit for Parkinson’s disease

Authors: Thomas Müller, Gabi Öhm, Kathrin Eilert, Katharina Möhr, Stephanie Rotter, Thomas Haas, Matthias Küchler, Sven Lütge, Marion Marg, Hartmut Rothe

Published in: Journal of Neural Transmission | Issue 6/2017

Login to get access

Abstract

Treatment of patients with Parkinson’s disease in specialized units is quite common in Germany. Data on the benefit of this hospitalization of patients with Parkinson’s disease on motor and non-motor symptoms in conjunction with standardized tests are rare. Objective was to determine the efficacy of this therapeutic setting. We scored disease severity and performed clinical tests, respectively, instrumental procedures under standardized conditions in consecutively referred in-patients initially and at the end of their hospital stay. There was a decrease of motor and non-motor symptoms. The extent of improvement of non-motor and motor symptoms correlated to each other. Performance of complex movement sequences became better, whereas execution of simple movement series did not ameliorate. The interval for the timed up and go test went down. We demonstrate the effectiveness of an in-patient stay in a specialized unit for Parkinson’s disease. Objective standardized testing supplements subjective clinical scoring with established rating scales.
Literature
go back to reference Berg D, Godau J, Seppi K, Behnke S, Liepelt-Scarfone I, Lerche S, Stockner H, Gaenslen A, Mahlknecht P, Huber H, Srulijes K, Klenk J, Fassbender K, Maetzler W, Poewe W (2013) The PRIPS study: screening battery for subjects at risk for Parkinson’s disease. Eur J Neurol 20:102–108CrossRefPubMed Berg D, Godau J, Seppi K, Behnke S, Liepelt-Scarfone I, Lerche S, Stockner H, Gaenslen A, Mahlknecht P, Huber H, Srulijes K, Klenk J, Fassbender K, Maetzler W, Poewe W (2013) The PRIPS study: screening battery for subjects at risk for Parkinson’s disease. Eur J Neurol 20:102–108CrossRefPubMed
go back to reference Chaudhuri KR, Martinez-Martin P (2008) Quantitation of non-motor symptoms in Parkinson’s disease. Eur J Neurol 15(Suppl 2):2–7CrossRefPubMed Chaudhuri KR, Martinez-Martin P (2008) Quantitation of non-motor symptoms in Parkinson’s disease. Eur J Neurol 15(Suppl 2):2–7CrossRefPubMed
go back to reference Chaudhuri KR, Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, Brown RG, Koller W, Barone P, Macphee G, Kelly L, Rabey M, Macmahon D, Thomas S, Ondo W, Rye D, Forbes A, Tluk S, Dhawan V, Bowron A, Williams AJ, Olanow CW (2006) International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Mov Disord 21:916–923CrossRefPubMed Chaudhuri KR, Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, Brown RG, Koller W, Barone P, Macphee G, Kelly L, Rabey M, Macmahon D, Thomas S, Ondo W, Rye D, Forbes A, Tluk S, Dhawan V, Bowron A, Williams AJ, Olanow CW (2006) International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Mov Disord 21:916–923CrossRefPubMed
go back to reference Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P, Ondo W, Abe K, Macphee G, Macmahon D, Barone P, Rabey M, Forbes A, Breen K, Tluk S, Naidu Y, Olanow W, Williams AJ, Thomas S, Rye D, Tsuboi Y, Hand A, Schapira AH (2007) The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international pilot study. Mov Disord 22:1901–1911CrossRefPubMed Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P, Ondo W, Abe K, Macphee G, Macmahon D, Barone P, Rabey M, Forbes A, Breen K, Tluk S, Naidu Y, Olanow W, Williams AJ, Thomas S, Rye D, Tsuboi Y, Hand A, Schapira AH (2007) The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international pilot study. Mov Disord 22:1901–1911CrossRefPubMed
go back to reference Fahn S, Elton R, Members of the UPDRS Development Committee (1987) Unified Parkinson’s Disease Rating Scale. Macmillan, New York, pp 153–163 Fahn S, Elton R, Members of the UPDRS Development Committee (1987) Unified Parkinson’s Disease Rating Scale. Macmillan, New York, pp 153–163
go back to reference Maetzler W, Kruger R, Müller T, Oertel W, Urban P, Warnecke T, Klucken J (2016) Wearable technique for the assessment of parkinson symptoms: what’s the future? Fortschr Neurol Psychiatr 84(Suppl 1):S48–S51PubMed Maetzler W, Kruger R, Müller T, Oertel W, Urban P, Warnecke T, Klucken J (2016) Wearable technique for the assessment of parkinson symptoms: what’s the future? Fortschr Neurol Psychiatr 84(Suppl 1):S48–S51PubMed
go back to reference Müller T, Woitalla D (2010) Quality of life, caregiver burden and insurance in patients with Parkinson’s disease in Germany. Eur J Neurol 17:1365–1369CrossRefPubMed Müller T, Woitalla D (2010) Quality of life, caregiver burden and insurance in patients with Parkinson’s disease in Germany. Eur J Neurol 17:1365–1369CrossRefPubMed
go back to reference Müller T, Schafer S, Kuhn W, Przuntek H (2000) Correlation between tapping and inserting of pegs in Parkinson’s disease. Can J Neurol Sci 27:311–315CrossRefPubMed Müller T, Schafer S, Kuhn W, Przuntek H (2000) Correlation between tapping and inserting of pegs in Parkinson’s disease. Can J Neurol Sci 27:311–315CrossRefPubMed
go back to reference Müller T, Voss B, Hellwig K, Josef SF, Schulte T, Przuntek H (2004) Treatment benefit and daily drug costs associated with treating Parkinson’s disease in a Parkinson’s disease clinic. CNS Drugs 18:105–111CrossRefPubMed Müller T, Voss B, Hellwig K, Josef SF, Schulte T, Przuntek H (2004) Treatment benefit and daily drug costs associated with treating Parkinson’s disease in a Parkinson’s disease clinic. CNS Drugs 18:105–111CrossRefPubMed
go back to reference Siderowf AD, Werner RM (2001) The EQ-5D—a generic quality of life measure—is a useful instrument to measure quality of life in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 70:817CrossRefPubMedPubMedCentral Siderowf AD, Werner RM (2001) The EQ-5D—a generic quality of life measure—is a useful instrument to measure quality of life in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 70:817CrossRefPubMedPubMedCentral
go back to reference Zampieri C, Salarian A, Carlson-Kuhta P, Aminian K, Nutt JG, Horak FB (2010) The instrumented timed up and go test: potential outcome measure for disease modifying therapies in Parkinson’s disease. J Neurol Neurosurg Psychiatry 81:171–176CrossRefPubMed Zampieri C, Salarian A, Carlson-Kuhta P, Aminian K, Nutt JG, Horak FB (2010) The instrumented timed up and go test: potential outcome measure for disease modifying therapies in Parkinson’s disease. J Neurol Neurosurg Psychiatry 81:171–176CrossRefPubMed
Metadata
Title
Benefit on motor and non-motor behavior in a specialized unit for Parkinson’s disease
Authors
Thomas Müller
Gabi Öhm
Kathrin Eilert
Katharina Möhr
Stephanie Rotter
Thomas Haas
Matthias Küchler
Sven Lütge
Marion Marg
Hartmut Rothe
Publication date
01-06-2017
Publisher
Springer Vienna
Published in
Journal of Neural Transmission / Issue 6/2017
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI
https://doi.org/10.1007/s00702-017-1701-3

Other articles of this Issue 6/2017

Journal of Neural Transmission 6/2017 Go to the issue